Samplify Systems debuts SAM2032, the first merchant ultrasound beamforming ASIC

Samplify Systems, Inc., a technology company focused on delivering innovative semiconductors, modules, and subsystem solutions to the ultrasound industry, today announces availability of the industry's first merchant beamforming ASIC—the SAM2032.  The highly integrated SAM2032 leverages all the benefits of Samplify's award-winning Autofocus™ technology in a receive beamforming ASIC offering the industry's lowest power consumption and highest performance compared to current FPGA-based beamformer implementations. The highly configurable ASIC provides the flexibility for ultrasound OEMs to simplifying software and system design thus speeding time to market for a wide range of machines from ultra-low power hand-helds, through mid-range and high-end carts.

The receive beamformer is at the heart of any ultrasound front-end electronics sub-system. The SAM2032 ASIC addresses a critical gap in the current FPGA implementation of these devices. While higher-end FPGAs can be used to develop a high-performance receive beamformer, their higher cost, higher power consumption, and larger size limits their use to premium console ultrasound machines. Conversely, lower-end FPGAs can be used as a cost-effective alternative, but their limited resources present system performance constraints.

"The availability of the SAM2032 is an exciting development in the ultrasound industry," says Danny Kreindler, Director for Ultrasound Products at Samplify Systems.  "By capturing all of the receive beamformer's complexity in an ASIC device, the SAM2032 delivers the only high-performance, low-power and low-cost solution in the commercial market. The availability of this ASIC enables existing and new entrants, in both the traditional OEM space and in emerging non-traditional ultrasound applications, to gain quick and easy access to premier beamforming technology that will significantly accelerate product development."

SOURCE Samplify Systems, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Nanomedicine using gas bubbles offers hope for lung cancer treatment